Literature DB >> 27004229

Fractionated radiotherapy combined with PD-1 pathway blockade promotes CD8 T cell-mediated tumor clearance for the treatment of advanced malignancies.

Tijana Martinov1, Brian T Fife1.   

Abstract

Entities:  

Year:  2016        PMID： 27004229      PMCID： PMC4779769          DOI： 10.3978/j.issn.2305-5839.2016.01.13

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  20 in total

Review 1.  The role of the PD-1 pathway in autoimmunity and peripheral tolerance.

Authors:  Brian T Fife; Kristen E Pauken
Journal:  Ann N Y Acad Sci       Date:  2011-01       Impact factor: 5.691

2.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

Review 3.  Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma.

Authors:  Christopher A Barker; Michael A Postow; Shaheer A Khan; Kathryn Beal; Preeti K Parhar; Yoshiya Yamada; Nancy Y Lee; Jedd D Wolchok
Journal:  Cancer Immunol Res       Date:  2013-07-25       Impact factor: 11.151

4.  Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.

Authors:  S F Slovin; C S Higano; O Hamid; S Tejwani; A Harzstark; J J Alumkal; H I Scher; K Chin; P Gagnier; M B McHenry; T M Beer
Journal:  Ann Oncol       Date:  2013-03-27       Impact factor: 32.976

5.  B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.

Authors:  Scott E Strome; Haidong Dong; Hideto Tamura; Stephen G Voss; Dallas B Flies; Koji Tamada; Diva Salomao; John Cheville; Fumiya Hirano; Wei Lin; Jan L Kasperbauer; Karla V Ballman; Lieping Chen
Journal:  Cancer Res       Date:  2003-10-01       Impact factor: 12.701

6.  Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

Authors:  Suzanne L Topalian; Mario Sznol; David F McDermott; Harriet M Kluger; Richard D Carvajal; William H Sharfman; Julie R Brahmer; Donald P Lawrence; Michael B Atkins; John D Powderly; Philip D Leming; Evan J Lipson; Igor Puzanov; David C Smith; Janis M Taube; Jon M Wigginton; Georgia D Kollia; Ashok Gupta; Drew M Pardoll; Jeffrey A Sosman; F Stephen Hodi
Journal:  J Clin Oncol       Date:  2014-03-03       Impact factor: 44.544

7.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

8.  Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma.

Authors:  Simon J Dovedi; Monique H M Melis; Robert W Wilkinson; Amy L Adlard; Ian J Stratford; Jamie Honeychurch; Timothy M Illidge
Journal:  Blood       Date:  2012-10-18       Impact factor: 22.113

9.  Radiation as an immunological adjuvant: current evidence on dose and fractionation.

Authors:  Sandra Demaria; Silvia C Formenti
Journal:  Front Oncol       Date:  2012-10-26       Impact factor: 6.244

10.  Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy.

Authors:  Antonio M Grimaldi; Ester Simeone; Diana Giannarelli; Paolo Muto; Sara Falivene; Valentina Borzillo; Francesca Maria Giugliano; Fabio Sandomenico; Antonella Petrillo; Marcello Curvietto; Assunta Esposito; Miriam Paone; Marco Palla; Giuseppe Palmieri; Corrado Caracò; Gennaro Ciliberto; Nicola Mozzillo; Paolo A Ascierto
Journal:  Oncoimmunology       Date:  2014-05-14       Impact factor: 8.110
View more
  5 in total

1.  Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.

Authors:  Narek Shaverdian; Aaron E Lisberg; Krikor Bornazyan; Darlene Veruttipong; Jonathan W Goldman; Silvia C Formenti; Edward B Garon; Percy Lee
Journal:  Lancet Oncol       Date:  2017-05-24       Impact factor: 41.316

2.  Risk of Developing Checkpoint Immune Pneumonitis and Its Effect on Overall Survival in Non-small Cell Lung Cancer Patients Previously Treated With Radiotherapy.

Authors:  Feliciano Barrón; Roberto Sánchez; Marisol Arroyo-Hernández; Carolina Blanco; Zyanya L Zatarain-Barrón; Rodrigo Catalán; Maritza Ramos-Ramírez; Andrés F Cardona; Diana Flores-Estrada; Oscar Arrieta
Journal:  Front Oncol       Date:  2020-09-29       Impact factor: 6.244

3.  Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy.

Authors:  Yuanzeng Min; Kyle C Roche; Shaomin Tian; Michael J Eblan; Karen P McKinnon; Joseph M Caster; Shengjie Chai; Laura E Herring; Longzhen Zhang; Tian Zhang; Joseph M DeSimone; Joel E Tepper; Benjamin G Vincent; Jonathan S Serody; Andrew Z Wang
Journal:  Nat Nanotechnol       Date:  2017-06-26       Impact factor: 39.213

Review 4.  Immune targets in the tumor microenvironment treated by radiotherapy.

Authors:  Omer M Ozpiskin; Lu Zhang; Jian Jian Li
Journal:  Theranostics       Date:  2019-01-30       Impact factor: 11.556

5.  Changes of Tumor Markers in Patients with Lung Cancer after Immunotherapy and Their Link with Inflammation in the Body.

Authors:  LiWei Liu; YuanChun Cai; XiaoLan Tao; Jing Huang; Min Han
Journal:  Comput Math Methods Med       Date:  2022-07-19       Impact factor: 2.809
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.